Impel Pharmaceuticals Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for patients suffering from central nervous system disease in the United States. Its lead product candidate is Trudhesa, an upper nasal formulation of dihydroergotamine for the acute treatment of migraine. The company is also developing INP105, an upper nasal formulation of olanzapine for the acute treatment of agitation and aggression in autism spectrum disorder; and INP107, an upper nasal formulation of carbidopa/levodopa, which has completed Phase IIa clinical trial for the treatment of OFF episodes in Parkinson's disease. Impel Pharmaceuticals Inc. was formerly known as Impel NeuroPharma, Inc. and changed its name to Impel Pharmaceuticals Inc. in April 2022. Impel Pharmaceuticals Inc. was incorporated in 2008 and is headquartered in Seattle, Washington.

Impel Pharmaceuticals Inc.

Cognate BioServices is a contract development and manufacturing organization specializing in cell and gene-mediated cell therapy. The company has supported the development of FDA-approved therapies and conducted numerous studies in this field.

Cognate BioServices

Impel Pharmaceuticals is focused on developing and providing transformative therapies for people suffering from diseases with high unmet needs across various disease areas in addition to the central nervous system (CNS), through the pioneering of an optimized approach to drug delivery. We offer and develop treatments that pair the Company’s proprietary Precision Olfactory Delivery (POD®) technology with well-established therapeutics. 

Impel Pharmaceuticals

Summer is a tough time of year for #migraine and #headaches. To best celebrate #freedom with your friends and family, be mindful of your triggers and keep your acute meds on hand.
 
Wishing everyone a safe and happy #IndependenceDay!

Trudhesa® (DHE mesylate) delivers a trusted #migraine therapeutic to the vascular-rich upper nasal space via the POD® device developed by our co-founder, CTO & CDO, John Hoekman. This results in IV-like efficacy at home - not via injection in an ER.

The Impel team proudly supports the #migraine community. Today we're wearing our #ShadesForMigraine to raise awareness about this complex, neurological disease that's more than just a #headache. 

#MHAM #MigraineAwareness

A second poster on preliminary real-world data underscores the need for non-oral treatment options for #migraine given the prevalence of pre-existing #gastrointestinal disorders among those prescribed with Trudhesa® (DHE mesylate).

See abstract P-160 in Headache: https://lnkd.in/eV8n_mNw

Read our press release to learn more: https://lnkd.in/eEkwReSh

#MHAM Dr. Sheena Aurora

Preliminary real-world data at #AHSAM suggest that concomitant preventive & acute medication use generally decreases in patients taking Trudhesa® (DHE mesylate) nasal spray, and that use of antinausea medications (common with DHE administered via IV) did not increase.

See abstract P-161 in Headache: https://lnkd.in/eV8n_mNw

Read yesterday's press release to learn more: https://lnkd.in/eEkwReSh 

#Migraine #MHAM Zubair Ahmed

Metric
Company Name	Impel Pharmaceuticals Inc.	Cognate BioServices
Symbol	IMPL
MSH ID	COM:IMPELPHARMA	COM:COGNATEBIOSERVICES
Market	STOCKS	PRIVATE
Sector	Healthcare	Healthcare & Health Services
Industry	Biotechnology	Biotechnology
Country	US	US
Stage	Debt	Series B
Employee Count	160
Website	impelpharma.com	cognatebioservices.com
LinkedIn	impel-pharma	cognate-bioservices
Founders

Metric
Market Cap	956K
Enterprise Value
Monthly Web Traffic	324
Web Traffic Growth	-0.20
Valuation
Raised Capital	50M

Metric
Revenue	12.65M
Revenue (LTM)
Revenue (NTM)
Gross Profit	6.16M
EBITDA	-83.18M
Operating Income	-83.18M
Net Income	-129.44M
EPS	-5.52
Diluted EPS	-5.52
Revenue 2022
Revenue 2023
Revenue 2024
Revenue 2025
Revenue 2026

Metric
Revenue Growth (LTM)
Revenue Growth (NTM)
Gross Profit Growth (LTM)
EBITDA Growth (LTM)
Net Income Growth (LTM)
14-Day Growth Score
28-Day Growth Score
90-Day Growth Score
365-Day Growth Score

Metric
Gross Profit Margin	0.53
Operating Profit Margin	-3.34
EBITDA Margin	-6.57
Net Profit Margin	-4.58
Return on Equity	1.33
Return on Assets	-2.74
Return on Capital Employed	0.78

COM:IMPELPHARMA

Impel Pharmaceuticals Inc.

Last Close

0.06

20/12 20:58

Market Cap

956K

Beta: -

Volume Today

720.03K

Avg: -

Company Overview

Market Metrics

Financial Performance

Growth Metrics

Profitability Ratios

Valuation Multiples

Operational Metrics

Cash Flow Metrics

Balance Sheet Metrics

Efficiency Metrics

Metric
P/E Ratio	-0.01
P/B Ratio	-0.01
Revenue Multiple (LTM)
Revenue Multiple (NTM)
EBITDA Multiple (LTM)
EBITDA Multiple (NTM)
Price to Sales Ratio	0.05
EV Multiple	1.66

Metric
Days Sales Outstanding	114.65
Days Payables Outstanding	136.95
Days Inventory Outstanding	251.74
Operating Cycle	366.39
Cash Conversion Cycle	229.44
Asset Turnover	0.60

Metric
Operating Cash Flow	-93.64M
Free Cash Flow	-95.02M
Cash Flow to Debt	-0.69
Operating Cash Flow/Sales	-3.77
Free Cash Flow Yield	-85.75

Metric
Cash & Equivalents	60.65M
Accounts Receivable	-6.09M
Inventory	8.43M
Goodwill
Debt to Capitalization	5.01
Debt to Assets	3.27
Current Ratio	0.19
Quick Ratio	0.05

Metric
Rule of 40 (LTM)
Rule of 40 (NTM)
Stock Comp to Revenue	0.23
R&D to Revenue	0.20
SG&A to Revenue	3.67